Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. Reply

N Engl J Med. 2024 Oct 10;391(14):1364-1365. doi: 10.1056/NEJMc2410841.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Boron Compounds / administration & dosage
  • Boron Compounds / adverse effects
  • Boron Compounds / therapeutic use
  • Bortezomib* / administration & dosage
  • Bortezomib* / adverse effects
  • Bortezomib* / therapeutic use
  • Dexamethasone* / administration & dosage
  • Dexamethasone* / adverse effects
  • Dexamethasone* / therapeutic use
  • Humans
  • Multiple Myeloma* / drug therapy

Substances

  • Bortezomib
  • Dexamethasone
  • belantamab mafodotin
  • Antibodies, Monoclonal, Humanized
  • Boron Compounds